EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.

Vinik AI, Wolin EM, Liyanage N, Gomez-Panzani E, Fisher GA

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists23 May 2016Cited by 73 (Europe PMC)

PMID27214300DOI10.4158/ep151172.orPepBankPUB-27214300

Publisher page PubMedAsk about this study

Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanRandomized controlled trialEfficacy outcome
In carcinoid syndrome patients, rescue days were lower with lanreotide (33.7%, CI 25.0%-42.4%) than placebo (48.5%, CI 39.6%-57.4%), difference -14.8% (CI -26.8% to -2.8%, P=.017).
In plain wordsLanreotide reduced days needing rescue octreotide compared with placebo.
Peptide
Lanreotide
Outcome
DecreaseDays with rescue octreotide use
Study
n = 115
Comparator
Placebo
Analysis
Primary
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
120 mg every 4 weeks · 16 weeksAs given in this study (human).
Measurements
Adjusted mean percentage of days with rescue octreotide
33.7%
lanreotide
95% CI, lanreotide
25 to 42.4%
lanreotide
Adjusted mean percentage of days with rescue octreotide
48.5%
placebo
95% CI, placebo
39.6 to 57.4%
placebo
Absolute difference, lanreotide vs placebo
−14.8%
between groups
95% CI of difference
−26.8 to −2.8%
between groups
P value
0.017 p-value
difference in rescue octreotide days
Source sentences
Summary
The adjusted mean (95% confidence interval [CI]) percentage of days with rescue octreotide use (primary endpoint) was significantly lower in the lanreotide (33.7%; 95% CI, 25.0%-42.4%) versus the placebo group (48.5%; 95% CI, 39.6%-57.4%), representing an absolute difference of -14.8% (95% CI, -26.8…
2 context sentences(design, population, supporting numbers)
Summary · context
This was a 16-week, randomized, double-blind, phase 3 trial (Clinicaltrials.gov: NCT00774930).
Summary · context
Patients with/without prior somatostatin analog (SSA) use were randomized to lanreotide depot/autogel 120 mg or placebo every 4 weeks, with access to short-acting octreotide as rescue medication.
Report a problemFND-2721430001
02HumanRandomized controlled trialEfficacy outcome
In carcinoid syndrome patients, lanreotide increased full/partial treatment success (≤3 rescue octreotide days during weeks 12 to 15) versus placebo (OR 2.4, 95% CI 1.1-5.3, P=.036).
In plain wordsLanreotide made full or partial treatment success (3 or fewer days of rescue octreotide in weeks 12 to 15) more likely than placebo.
Peptide
Lanreotide
Outcome
IncreaseFull or partial treatment success
Study
n = 115
Comparator
Placebo
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
120 mg every 4 weeks · 16 weeksAs given in this study (human).
Measurements
Odds ratio of full or partial treatment success
2.4 odds ratio
lanreotide vs placebo
95% CI of odds ratio
1.1 to 5.3 odds ratio
lanreotide vs placebo
P value
0.036 p-value
treatment success
Source sentences
Summary
The odds ratio of full/partial treatment success (≤3 days short-acting octreotide use weeks 12 to 15) was significantly greater with lanreotide than placebo (2.4; 95% CI, 1.1-5.3; P = .036).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a 16-week, randomized, double-blind, phase 3 trial (Clinicaltrials.gov: NCT00774930).
Summary · context
Patients with/without prior somatostatin analog (SSA) use were randomized to lanreotide depot/autogel 120 mg or placebo every 4 weeks, with access to short-acting octreotide as rescue medication.
Report a problemFND-2721430002
03HumanNon-randomized trialSafety outcome
In carcinoid syndrome patients, lanreotide was well tolerated and no new safety concerns were identified.
In plain wordsPatients tolerated lanreotide well, and the study identified no new safety concerns.
Peptide
Lanreotide
Outcome
Not applicableSafety and tolerability
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
120 mg every 4 weeks · 16 weeksAs given in this study (human).
Source sentences
Summary
No new safety concerns were identified, and lanreotide was well tolerated.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a 16-week, randomized, double-blind, phase 3 trial (Clinicaltrials.gov: NCT00774930).
Summary · context
Patients with/without prior somatostatin analog (SSA) use were randomized to lanreotide depot/autogel 120 mg or placebo every 4 weeks, with access to short-acting octreotide as rescue medication.
Report a problemFND-2721430003

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00774930

An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome

Ipsenn = 115May 2009 to Dec 2015

Carcinoid Syndrome

Trial page ClinicalTrials.govUpdated 14 Oct 2022

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.